Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.49 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19507106 | 0.90 | NLRP3 (0.44) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507109 | 0.89 | NLRP3 (0.48) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507108 | 0.88 | LARS1 (0.44) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL20932982 | 0.87 | NLRP3 (0.55) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL20932975 | 0.84 | NLRP3 (0.45) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507897 | 0.84 | NLRP3 (0.54) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL30145289 | 0.84 | NLRP3 (0.54) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507107 | 0.83 | NLRP3 (0.55) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507091 | 0.83 | SOAT2 (0.46) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19508017 | 0.81 | NLRP3 (0.48) | NLRP3SOAT2MYCSOAT1MAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395241-A1 | NLRP MODULATORS | NLRP1, NLRP3, NOD1 | NLRP3 2/4885SOAT2 3331/4885MYC 4601/4885 |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885SOAT2 2587/4885MYC 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.